Laura Valiña

Laura Valiña

Auto-generated profile, based on publicly available information

Laura Valiña

Department of Laboratory Medicine, Hospital Universitari Son Espases, 07120 Palma, Balearic Islands, Spain

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2020 in Cells
Verified
Journal Article
Open access
PDF file
PMPatricia Mondelo
Patricia Mondelo
CRCarmela Rodríguez-López
Carmela Rodríguez-López
LVLaura Valiña
Laura Valiña
SASantiago Aguín
Santiago Aguín
LLLuis Leon-Mateos
Luis Leon-Mateos
RLRafael López-López
Rafael López-López
MET alterations may provide a potential biomarker to evaluate patients who will benefit from treatment with MET inhibitors. Therefore, the purpose of the present study is to investigate the utility of a liquid biopsy-based strategy to assess MET alterations in cancer patients. We analyzed MET amplification in circulating free DNA (cfDNA) from 174 patients with cancer and 49 healthy controls and demonstrated the accuracy of the analysis to detect its alteration in patients. Importantly, a significant correlation between cfDNA concentration and MET copy number (CN) in cancer patients (r = 0.57, p <10−10) was determined. Furthermore, we evaluated two approaches to detect the presence of MET on circulating tumor cells (CTCs), using the CellSearch® and Parsortix systems and monitored patients under anti-EGFR treatment (n = 30) combining both cfDNA and CTCs analyses. This follow-up provides evidence for the potential of MET CN assessment when patients develop resistance to anti-EGFR therapy and a significant association between the presence of CTCs MET+ and the Overall Survival (OS) in head and neck cancer patients (P = 0.05; HR = 6.66). In conclusion, we develop specific and noninvasive assays to monitor MET status in cfDNA/CTCs and demonstrate the utility of plasma MET CN determination as a biomarker for monitoring the appearance of resistance to anti-EGFR therapy.

1 September 2017 in Clinical Biochemistry
Verified
Journal Article
Closed access
Macià Sureda-VivesMacià Sureda-Vives
Macià Sureda-Vives
DMDaniel Morell-Garcia
Daniel Morell-Garcia
ARAna Rubio-Alaejos
Ana Rubio-Alaejos
LVLaura Valiña
Laura Valiña
JRJuan Robles
Juan Robles
JBJosep Miquel Bauça
Josep Miquel Bauça